Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Amplitude Titration to Improve ECT Clinical Outcomes

NCT05699226 · View on ClinicalTrials.gov ↗

Study Summary

A randomized controlled trial will compare hippocampal neuroplasticity, antidepressant, and cognitive outcomes between individualized amplitude and fixed 800 mA amplitude ECT in older depressed subjects (n = 25 per group, n = 50 total). Relative to fixed 800 mA ECT: H1: Individualized amplitude arm will have improved RUL antidepressant outcome (IDS-C30 response rates and reduced BT electrode placement switch at V2). H2: Individualized amplitude arm will have improved cognitive outcomes (DKEFS-Verbal Fluency

Interventions

  • DEVICE Soterix Medical Incorporated 4x1 adapter
  • DEVICE Traditional ECT device

Study Locations (1)

New Mexico

  • University of New Mexico Health Science Center — Albuquerque

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2023-09-14
Est. Completion 2028-01-01
Phase NA

Sponsor

University of New Mexi

107 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05699226

The ClinicalTrials.gov registry entry for NCT05699226 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of New Mexi, which has 107 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions — of which Soterix Medical Incorporated 4x1 adapter is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05699226 reports 1 study location spanning 1 distinct geographic area — top geographies include New Mexico. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05699226 about?

NCT05699226 is a clinical study titled "Amplitude Titration to Improve ECT Clinical Outcomes". A randomized controlled trial will compare hippocampal neuroplasticity, antidepressant, and cognitive outcomes between individualized amplitude and fixed 800 mA amplitude ECT in older depressed subjects (n = 25 per group, n = 50 total). Relative to fixed 800 mA ECT: H1: Individualized amplitude arm...

What is the current status of trial NCT05699226?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2023-09-14. Estimated completion is 2028-01-01.

What conditions does trial NCT05699226 study?

This clinical trial studies the following conditions: Depression, Cognitive Change, ECT. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05699226?

The interventions under investigation include: Soterix Medical Incorporated 4x1 adapter (DEVICE), Traditional ECT device (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05699226?

This trial is sponsored by University of New Mexi, which has 107 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05699226 being conducted?

This trial has 1 study location across New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial